Stock Market Today, June 23: D-Wave Quantum Jumps After Trump Signs Executive Orders Boosting Quantum Adoption

D-Wave Quantum closed at $25.03, up 2.29%, after President Trump signed executive orders to accelerate U.S. quantum adoption and quantum-resistant encryption. Trading volume was 46.5 million shares, about 36% above its three-month average of 34.2 million, while investors also focused on commercialization progress and upcoming quarterly earnings. The article notes prior Commerce Department support tied to a $100 million grant and share issuance, reinforcing expectations for demand and funding support.

Analysis

The policy signal matters less as a one-day headline than as a valuation-duration extender for the entire quantum complex. QBTS is the clearest tactical beneficiary because the market is now underwriting a faster path from “research optionality” to “government-backed procurement,” which can pull forward customer validation and reduce the perceived financing discount. That said, the move also raises the bar: once the stock starts pricing in national-strategy relevance, any missed milestone on commercialization, bookings, or gross-margin progression can trigger a sharper de-rating than in a pure story stock.

Second-order, the executive orders likely help the incumbent-platform names with the strongest lobbying or federal contracting adjacency first, while making the weaker balance-sheet players more dependent on capital markets. That creates an important asymmetry: a rising-tide trade can still leave the most diluted names vulnerable if investors conclude they must issue stock into strength to fund the next 12-18 months. In other words, policy support may improve demand certainty but can simultaneously accelerate competitive separation between the best-capitalized operator and the rest of the peer group.

The contrarian miss is timing. The market may be extrapolating 2028 procurement language into near-term revenue, but commercialization in quantum usually advances in uneven jumps, not linear curves, and the revenue bridge is likely to remain small relative to today’s implied growth multiple. If the next earnings print does not show a meaningful step-up in backlog, pilot-to-production conversion, or customer concentration improvement, the stock is exposed to a classic “buy the headline, sell the evidence” reversal over the next 2-8 weeks.

For peers, relative weakness in IONQ and RGTI despite the same policy umbrella suggests the market is already discriminating on execution quality rather than sector beta. That is constructive for a pair structure: if the catalyst is real, it should show up first in the names with the clearest government linkage and financing visibility. If it is just sentiment, the group can retrace quickly as soon as macro risk-off resumes and high-duration tech is repriced.

Key Decisions for Investors

• Long QBTS / short RGTI in equal dollar terms for 2-6 weeks: express policy-benefit dispersion while isolating execution quality; target 10-15% relative outperformance if commercialization updates are credible, stop if QBTS loses the policy premium on weak guidance.
• Buy QBTS call spreads into the next earnings date: favorable for a defined-risk upside capture if the company confirms backlog/booking acceleration, with limited downside if the market reverts to fundamentals.
• Short-dated hedge on QBTS via puts or collars after any post-policy spike: if the stock trades materially above the pre-earnings range, use optionality to protect against a “headline-to-evidence” fade over 1-2 months.
• Avoid chasing IONQ/RGTI on the same news; use rallies in the weaker peers as opportunities to fade, since the policy impulse is likely to separate winners from laggards rather than lift all boats equally.